RSK2/RPS6KA3/p90RSK2 Cancer Research Results

RSK2/RPS6KA3/p90RSK2, Serine/threonine protein kinase / MAPK-ERK downstream effector: Click to Expand ⟱
Source:
Type:

RPS6KA3 - Ribosomal Protein S6 Kinase A3 / RSK2

Abbreviation: RSK2, RPS6KA3, p90RSK2

Type: Serine/threonine protein kinase / MAPK-ERK downstream effector

Function: RSK2 is a member of the p90 ribosomal S6 kinase family activated primarily downstream of ERK1/2. It regulates transcription, protein synthesis, cell-cycle progression, proliferation, survival, migration, differentiation, and stress responses through phosphorylation of multiple nuclear and cytoplasmic substrates.

Cancer: ↑ Frequently activated or overexpressed in selected cancers and can promote proliferation, survival, migration, invasion, transformation, and treatment resistance downstream of MAPK/ERK signaling. RSK2 inhibition or knockdown can suppress tumor-cell growth and oncogenic signaling in experimental models.
Scientific Papers found: Click to Expand⟱
8161- LapC,    Lapachol is a novel ribosomal protein S6 kinase 2 inhibitor that suppresses growth and induces intrinsic apoptosis in esophageal squamous cell carcinoma cells
- in-vitro, ESCC, KYSE-30 - in-vitro, ESCC, KYSE450 - in-vitro, ESCC, KYSE-510
RSK2/RPS6KA3/p90RSK2↓, Herein, we report that lapachol is a novel ribosomal protein S6 kinase 2 (RSK2) inhibitor that suppresses growth and induces intrinsic apoptosis in ESCC cells.
TumCG↓,
Apoptosis↑,
Casp3↑, We also found that lapachol induces mitochondria-mediated cellular apoptosis by activating caspases-3, -7, and PARP, inducing the expression of cytochrome c and BAX by inhibiting downstream molecules of RSK2.
Casp7↑,
PARP↑,
Cyt‑c↑,
BAX↑,
p‑CREB↓, Results indicated that the expression of the phosphorylated CREB, ATF1, and histone H3 proteins is dose‐dependently inhibited by lapachol treatment, whereas the level of the phosphorylated RSK protein is not changed
ATF1↓,
H3↓,
CycB/CCNB1↓, Results showed that lapachol reduces expression of phosphorylated histone H3 and the expression of cyclin B1, cyclin D3, cyclin D1, and phosphorylation of CDK2 (
cycD1/CCND1↓,
p‑CDK2↓,


Showing Research Papers: 1 to 1 of 1

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 1

Pathway results for Effect on Cancer / Diseased Cells:


NA, unassigned(tgid=0) ⓘ

ATF1↓, 1,   RSK2/RPS6KA3/p90RSK2↓, 1,  

Core Metabolism/Glycolysis(tgid=4) ⓘ

p‑CREB↓, 1,  

Cell Death(tgid=5) ⓘ

Apoptosis↑, 1,   BAX↑, 1,   Casp3↑, 1,   Casp7↑, 1,   Cyt‑c↑, 1,  

Transcription & Epigenetics(tgid=7) ⓘ

H3↓, 1,  

DNA Damage & Repair(tgid=10) ⓘ

PARP↑, 1,  

Cell Cycle & Senescence(tgid=11) ⓘ

p‑CDK2↓, 1,   CycB/CCNB1↓, 1,   cycD1/CCND1↓, 1,  

Proliferation, Differentiation & Cell State(tgid=12) ⓘ

TumCG↓, 1,  
Total Targets: 14

Pathway results for Effect on Normal Cells:


Total Targets: 0

Scientific Paper Hit Count for: RSK2/RPS6KA3/p90RSK2, Serine/threonine protein kinase / MAPK-ERK downstream effector
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:%  Target#:1768  State#:%  Dir#:1
  wNotes=on  sortOrder:rid,rpid

 

Home Page